NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Cogent Biosciences, Inc. COGT
9 fiscal years on record · USD · FY2025 reported · SEC filings only
$-328.9M
$-266.0M
Growth
—
Revenue, FY2025 · full 9-year series below
Revenue $M
Net income $M
FY2020 · Revenue 7.9 · Net income -74.8
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2020 · Operating -1044.3% · Net -950.4%
ROE
FY2025 · ROE -73.7%
Each USD of equity lost 74 cents this year.
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.3 | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.3 | −0.3 | −0.2 | −0.1 | · | · | · | · | · |
| Income tax $B | 0.0 | · | · | · | · | · | · | · | · |
| Net income $B | −0.3 | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.3 | −0.2 | −0.2 | −0.1 | −0.1 | · | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −2.16 | −1.94 | −1.94 | −1.73 | −1.87 | −16.17 | −4.18 | −1.39 | −2.51 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · |
| ROE % | −73.7 | −99.5 | −74.9 | −59.7 | −32.2 | −56.2 | −69.2 | −606.5 | · |
| Shares out B | 0.16 | 0.11 | 0.09 | 0.07 | 0.04 | 0.03 | 0.01 | 0.03 | 0.02 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 4 failures in 36 reconciliationsAUDITED
Reconciled in 5 of 19 fiscal years. 40 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente4 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2016